查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2048043

青黴素G鈉市場 - 全球產業規模、佔有率、趨勢、機會、預測：銷售管道、最終用途、地區和競爭格局，2021-2031年

Penicillin G Sodium Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Sales Channel, By End Use, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

青黴素G鈉是一種窄頻譜BETA-內醯胺類抗生素，可經由靜脈或肌肉注射用於治療梅毒、腦膜炎和心內膜炎等嚴重細菌感染疾病。預計到2025年，青黴素G鈉的全球市場規模將從2.8011億美元成長到2031年的3.8229億美元，複合年成長率為5.32%。

這一成長主要受全球感染疾病率上升以及該藥物在人類和動物健康中發揮的關鍵作用所驅動，即使新的治療方法不斷湧現，也能確保穩定的需求。此外，新興市場對更經濟的醫療保健解決方案的需求不斷成長，也持續推動這種成熟活性成分的應用。然而，由於供應鏈脆弱以及生產專利到期藥物分子所帶來的經濟挑戰，該市場面臨許多障礙。生產設施的集中也使得該行業極易受到供應中斷和價格壓力的影響。根據歐洲藥品協會（Medicines for Europe）預測，到2025年，歐洲16個國家將有240種抗生素被從藥品目錄中移除，並出現385種供不應求，這凸顯了市場持續擴張面臨的重大風險。

市場概覽
預測期 2027-2031
市場規模：2025年 2.8011億美元
市場規模：2031年 3.8229億美元
複合年成長率：2026-2031年 5.32%
成長最快的細分市場 腦膜炎
最大的市場 亞太地區

市場促進因素

青黴素G鈉市場需求的主要驅動力是梅毒和其他性行為感染傳染病的死灰復燃，凸顯了其作為第一線治療藥物的關鍵作用。儘管有其他抗生素可供選擇，但這種活性成分仍然是黃金標準，尤其是在需要靜脈注射以確保療效的嚴重細菌感染疾病病例中，例如神經梅毒和先天性性行為感染。這一日益嚴峻的公共衛生挑戰催生了對預防嚴重長期健康損害的迫切且持續的需求。根據美國疾病管制與預防中心（CDC）預測，美國先天性梅毒病例數將連續第12年成長，2024年將達到近4,000例。同時，獸醫和畜牧業中抗生素使用量的增加也顯著推高了全球消費量，因為青黴素G鈉對於控制肉類用動物的細菌感染疾病至關重要。為了加強畜牧業生產以滿足全球蛋白質需求，可靠的抗菌療法對於維護畜群健康和防止疾病爆發造成的經濟損失至關重要。美國食品藥物管理局(FDA) 的報告顯示，2023 年至 2024 年，用於肉類用動物的重要抗菌藥物的銷售額預計將成長 16%，這反映出獸醫領域的強勁需求。這些藥物應用範圍廣泛，涵蓋人類和動物健康，並支持大規模生產。 Centrient Pharmaceuticals 的營運使全球約 15.7 億患者在上年度獲得了治療。

市場挑戰

青黴素G鈉的全球市場受到供應鏈脆弱性和專利到期活性藥物成分（API）生產盈利下降的嚴重限制。由於這種成熟抗生素的利潤率低於新型療法，其生產日益集中在少數幾個製造地。這種地域和設施上的集中造成了結構性缺陷，任何單一的品質問題或物流中斷都可能導致大範圍的產品短缺。因此，製造商往往缺乏滿足全球需求的實際產能，而市場也難以將穩定的臨床需求轉化為實際收入。這種固有的不穩定性直接阻礙了市場擴張，削弱了買家的信心，迫使醫療機構尋求替代治療方法以確保病患安全。這些干擾的持續存在造成了不穩定的商業環境，阻礙了長期採購合約和投資的簽訂。近期產業分析也凸顯了這種供需缺口的嚴重性。歐洲醫院藥劑師協會 (EAHP) 2025 年的一項調查顯示，63% 的醫院藥劑師認為抗菌藥物是受供不應求影響最大的藥物類別，凸顯了市場穩定成長面臨的重大障礙。

市場趨勢

重塑市場格局的關鍵趨勢之一是原料藥（原料藥）生產的回流和在地化。各國都在尋求減少對亞洲供應鏈的依賴，以增強國內醫療保健的韌性。各國政府日益將抗生素生產視為國家安全優先事項，並因此推出補貼計劃，鼓勵將重要的BETA-內醯胺類藥物生產轉移回國內。這種策略轉變迫使製造商在歐洲和北美建立區域生產基地，從而保護供應鏈免受波動和貿易中斷的影響。例如，歐盟委員會於2025年3月發布的《關鍵藥物法案》提案，撥款8,850萬歐元用於投資戰略項目，以加強歐盟關鍵藥物的生產能力。同時，為了提高生產經濟效益，該產業正從傳統的溶劑密集型化學製程轉向酶法和環境友善合成方法。這項技術進步在青黴素G鈉的合成中採用了生物催化劑，顯著降低了能源消耗和廢棄物，同時提高了產量和純度。在成本高度敏感的市場中，這是維持獲利能力的關鍵因素。這種永續的生產方式使企業能夠在不犧牲產量的情況下實現嚴格的環境目標。例如，Centrient Pharmaceuticals在其2025年6月發布的《2024年ESG報告》中詳細闡述了其透過最佳化關鍵製造地的製程等舉措，在2024年實現了範圍1和範圍2溫室氣體排放較基準值降低8%的目標。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球青黴素G鈉市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 銷售管道（直接、間接）
    • 依應用領域（細菌感染疾病、梅毒、預防、腦膜炎、聯合治療、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美青黴素G鈉市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲青黴素G鈉市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區青黴素G鈉市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲青黴素G鈉市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美青黴素G鈉市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球青黴素G鈉市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • North China Pharmaceutical Company.Ltd
  • Henan Xinxiang Huaxing Pharmaceutical
  • CSPC ZHONGNUO PHARMACEUTICAL（SHIJIAZHUANG）CO., LTD.
  • Shandong Lukang Pharmaceutical Group Co., Ltd.
  • Kangyuan Pharmaceutical Group
  • Harbin Pharmaceutical Group

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 28999

The global market for Penicillin G Sodium, a narrow-spectrum beta-lactam antibiotic used intravenously or intramuscularly for severe bacterial infections such as syphilis, meningitis, and endocarditis, is projected to expand from USD 280.11 Million in 2025 to USD 382.29 Million by 2031, achieving a compound annual growth rate of 5.32%. This growth is primarily fueled by the increasing worldwide incidence of infectious diseases and the drug's indispensable role in both human and animal health, ensuring consistent demand even with the availability of newer treatments.Additionally, the push for more economical healthcare solutions in emerging economies continuously stimulates the adoption of this well-established active pharmaceutical ingredient. However, the market faces significant hurdles due to fragile supply chains and the economic challenges of producing off-patent molecules. The concentration of manufacturing facilities makes the sector susceptible to disruptions and pricing pressures, as evidenced by 240 antibiotic withdrawals and 385 reported shortages across 16 European countries in 2025, according to Medicines for Europe, highlighting critical risks to sustained market expansion.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 280.11 Million
Market Size 2031USD 382.29 Million
CAGR 2026-20315.32%
Fastest Growing SegmentMeningitis
Largest MarketAsia Pacific

Market Driver

The market for Penicillin G Sodium is primarily propelled by the re-emergence of syphilis and other sexually transmitted infections, underscoring its essential role as a first-line therapy. Despite other antibiotic options, this active pharmaceutical ingredient remains the gold standard for severe bacterial cases, especially neurosyphilis or congenital transmission requiring intravenous administration for effectiveness. This escalating public health challenge creates urgent and sustained demand to avert severe long-term health consequences, with the Centers for Disease Control and Prevention reporting a twelfth consecutive annual rise in congenital syphilis cases in the U.S., reaching nearly 4,000 in 2024.Concurrently, the increasing use of antibiotics in veterinary medicine and livestock management significantly boosts global consumption, as Penicillin G Sodium is crucial for controlling bacterial infections in food-producing animals. The need to intensify livestock production for global protein demand necessitates reliable antimicrobial therapies to maintain herd health and prevent economic losses from disease outbreaks. The U.S. Food and Drug Administration reported a 16% increase in sales of medically important antimicrobial drugs for food-producing animals between 2023 and 2024, reflecting robust veterinary demand. This extensive application across human and animal health sectors supports the massive manufacturing scale, with Centrient Pharmaceuticals' operations facilitating approximately 1.57 billion patient treatments globally in the prior year.

Market Challenge

The global market for Penicillin G Sodium is substantially constrained by vulnerabilities in its supply chain and the decreasing financial appeal of manufacturing off-patent active pharmaceutical ingredients. Given that this mature antibiotic yields lower profit margins compared to novel therapeutics, production has increasingly centralized into a limited number of manufacturing sites. This concentration, both geographically and in terms of facilities, creates a structural weakness where a single quality issue or logistical interruption can lead to widespread product unavailability. As a result, the market struggles to convert consistent clinical demand into actual revenue, since manufacturers often lack the physical capacity to meet global requirements.This inherent instability directly impedes market expansion by eroding buyer confidence and compelling healthcare providers to seek alternative treatments to ensure patient safety. The ongoing nature of these disruptions fosters a volatile commercial environment, discouraging long-term procurement agreements and investment. The severity of this gap between supply and demand is underscored by recent sector analyses; in 2025, 63% of hospital pharmacists surveyed by the European Association of Hospital Pharmacists identified antimicrobial agents as the medication category most frequently affected by supply shortages, highlighting a critical barrier to stable market growth.

Market Trends

A significant trend reshaping the market is the reshoring and localization of API manufacturing, as countries aim to reduce their dependence on Asian supply networks to bolster national health resilience. Governments are increasingly viewing antibiotic production as a national security priority, leading to subsidies that encourage the repatriation of essential beta-lactam manufacturing. This strategic shift is compelling manufacturers to establish regional production hubs in Europe and North America, thereby shielding supply chains from volatility and trade disruptions. For instance, the European Commission's 'Proposal for a Critical Medicines Act' in March 2025 allocated €88.5 million to invest in strategic projects that enhance the EU's manufacturing capacity for critical medicines.Simultaneously, the industry is transitioning to enzymatic and green synthesis methods, replacing traditional solvent-intensive chemical processes to enhance production economics. This technological evolution employs biocatalysts for Penicillin G Sodium synthesis, substantially reducing energy consumption and waste while improving yield purity-a crucial factor for sustaining margins in this cost-sensitive market. Such sustainable manufacturing practices enable companies to achieve stringent environmental targets without compromising output. Centrient Pharmaceuticals, for example, reported an 8% reduction in its Scope 1 and 2 greenhouse gas emissions in 2024 compared to its baseline, driven by targeted initiatives including process optimizations at key manufacturing sites, as detailed in its June 2025 '2024 ESG Report'.

Key Market Players

  • North China Pharmaceutical Company.Ltd
  • Henan Xinxiang Huaxing Pharmaceutical
  • CSPC ZHONGNUO PHARMACEUTICAL (SHIJIAZHUANG) CO., LTD.
  • Shandong Lukang Pharmaceutical Group Co., Ltd.
  • Kangyuan Pharmaceutical Group
  • Harbin Pharmaceutical Group

Report Scope

In this report, the Global Penicillin G Sodium Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Penicillin G Sodium Market, By Sales Channel

  • Direct
  • Indirect

Penicillin G Sodium Market, By End Use

  • Bacterial Infections
  • Syphilis
  • Prophylaxis
  • Meningitis
  • Combination Therapies
  • Others

Penicillin G Sodium Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Penicillin G Sodium Market.

Available Customizations:

Global Penicillin G Sodium Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Penicillin G Sodium Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Sales Channel (Direct, Indirect)
    • 5.2.2. By End Use (Bacterial Infections, Syphilis, Prophylaxis, Meningitis, Combination Therapies, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Penicillin G Sodium Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Sales Channel
    • 6.2.2. By End Use
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Penicillin G Sodium Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Sales Channel
        • 6.3.1.2.2. By End Use
    • 6.3.2. Canada Penicillin G Sodium Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Sales Channel
        • 6.3.2.2.2. By End Use
    • 6.3.3. Mexico Penicillin G Sodium Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Sales Channel
        • 6.3.3.2.2. By End Use

7. Europe Penicillin G Sodium Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Sales Channel
    • 7.2.2. By End Use
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Penicillin G Sodium Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Sales Channel
        • 7.3.1.2.2. By End Use
    • 7.3.2. France Penicillin G Sodium Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Sales Channel
        • 7.3.2.2.2. By End Use
    • 7.3.3. United Kingdom Penicillin G Sodium Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Sales Channel
        • 7.3.3.2.2. By End Use
    • 7.3.4. Italy Penicillin G Sodium Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Sales Channel
        • 7.3.4.2.2. By End Use
    • 7.3.5. Spain Penicillin G Sodium Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Sales Channel
        • 7.3.5.2.2. By End Use

8. Asia Pacific Penicillin G Sodium Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Sales Channel
    • 8.2.2. By End Use
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Penicillin G Sodium Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Sales Channel
        • 8.3.1.2.2. By End Use
    • 8.3.2. India Penicillin G Sodium Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Sales Channel
        • 8.3.2.2.2. By End Use
    • 8.3.3. Japan Penicillin G Sodium Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Sales Channel
        • 8.3.3.2.2. By End Use
    • 8.3.4. South Korea Penicillin G Sodium Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Sales Channel
        • 8.3.4.2.2. By End Use
    • 8.3.5. Australia Penicillin G Sodium Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Sales Channel
        • 8.3.5.2.2. By End Use

9. Middle East & Africa Penicillin G Sodium Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Sales Channel
    • 9.2.2. By End Use
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Penicillin G Sodium Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Sales Channel
        • 9.3.1.2.2. By End Use
    • 9.3.2. UAE Penicillin G Sodium Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Sales Channel
        • 9.3.2.2.2. By End Use
    • 9.3.3. South Africa Penicillin G Sodium Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Sales Channel
        • 9.3.3.2.2. By End Use

10. South America Penicillin G Sodium Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Sales Channel
    • 10.2.2. By End Use
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Penicillin G Sodium Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Sales Channel
        • 10.3.1.2.2. By End Use
    • 10.3.2. Colombia Penicillin G Sodium Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Sales Channel
        • 10.3.2.2.2. By End Use
    • 10.3.3. Argentina Penicillin G Sodium Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Sales Channel
        • 10.3.3.2.2. By End Use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Penicillin G Sodium Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. North China Pharmaceutical Company.Ltd
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Henan Xinxiang Huaxing Pharmaceutical
  • 15.3. CSPC ZHONGNUO PHARMACEUTICAL (SHIJIAZHUANG) CO., LTD.
  • 15.4. Shandong Lukang Pharmaceutical Group Co., Ltd.
  • 15.5. Kangyuan Pharmaceutical Group
  • 15.6. Harbin Pharmaceutical Group

16. Strategic Recommendations

17. About Us & Disclaimer